EUVIMEDEUVIMED entdecken
Fall-Kontroll-Studie

Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study

Mara Caroprese, Manuel Conson, Angela Barillaro, Chiara Feoli, Laura Cella, Caterina Oliviero, Stefania Clemente, Antonio Farella, Carmine DE Angelis, Mario Giuliano, Grazia Arpino, Stefania Scala und 1 weitere

Anticancer Research · 2024-08 · 44 (8) · 3501-3506

DOI: 10.21873/anticanres.17170 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Anticancer Research, online erschienen am 26.07.2024. Verfasst von Mara Caroprese und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Neoadjuvant systemic therapy (NAT) in breast cancer can make tumors resectable or reduce the extent of surgery needed for locally advanced cancers. It can also better prevent distant relapse and possibly modulate drug therapy by adjusting adjuvant therapy (AD) based on the response to NAT, either by escalating or de-escalating the treatment. However, clear evidence of improved outcomes is currently missing. Here, we report on breast cancer patients treated with NAT at our institution. PATIENTS AND METHODS: One hundred twenty-seven patients treated at our Radiation Oncology department between 2004 and 2021 were retrospectively analyzed. All patients had localized or locally advanced breast cancer, were treated with NAT, and received postoperative radiotherapy. The outcomes considered were overall survival (OS), loco-regional recurrence-free survival (LRRFS), and distant metastases-free survival (DMFS). A matched patient population treated with AD during the same period and at the same center was used for comparison. RESULTS: The 5-year predicted OS was 87% in the NAT group and 81.5% in the AD group (p-value=0.179), while LRRFS was 93.2% in the NAT group and 100% in the AD group (p=0.005). The 5-year predicted DMFS was 84.6% in the NAT group and 82.1% in AD patients (p=0.367). In the NAT group, the only prognostic factor significantly related to improved outcomes was the pathological node response, with an OS of 95.6% in patients without residual node disease compared to 75.1% in patients with evidence of residual node disease. CONCLUSION: Our study, despite the limitations of a small number of patients and its retrospective nature, confirms the data of previous larger studies. In terms of DMFS and OS, NAT is at least as effective as AD. NAT represents a great opportunity for personalized modulation of treatment in node-positive breast cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyHumansFemaleMiddle AgedChemotherapy, AdjuvantAgedCase-Control StudiesAdultRetrospective StudiesDisease-Free SurvivalNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Breast canceradjuvant therapyneoadjuvant systemic therapy

Autor:innen und Institutionen

  • Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.
  • Institute of Biostructures and Bioimaging, National Research Council, Naples, Italy.
  • University Hospital Federico II, Naples, Italy.
  • Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  • Microenvironment Molecular Targets, National Cancer Institute Fondazione G. Pascale, Naples, Italy.
  • Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy; Roberto.pacelli@unina.it.

Zitieren

APA

Caroprese, M., Conson, M., Barillaro, A., Feoli, C., Cella, L., Oliviero, C., Clemente, S., Farella, A., DE Angelis, C., Giuliano, M., Arpino, G., Scala, S., & Pacelli, R. (2024). Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study. Anticancer Research, 44(8), 3501-3506. https://doi.org/10.21873/anticanres.17170

Vancouver

Caroprese M, Conson M, Barillaro A, Feoli C, Cella L, Oliviero C, et al. Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study. Anticancer Research. 2024;44(8):3501-3506. doi:10.21873/anticanres.17170

BibTeX
@article{Caroprese2024,
  author = {Caroprese, Mara and Conson, Manuel and Barillaro, Angela and Feoli, Chiara and Cella, Laura and Oliviero, Caterina and Clemente, Stefania and Farella, Antonio and DE Angelis, Carmine and Giuliano, Mario and Arpino, Grazia and Scala, Stefania and Pacelli, Roberto},
  title = {Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study},
  journal = {Anticancer Research},
  year = {2024},
  volume = {44},
  number = {8},
  pages = {3501--3506},
  doi = {10.21873/anticanres.17170}
}
Kostenlos starten →